UCB (OTCMKTS:UCBJY) Sees Large Volume Increase - Still a Buy?

Key Points

• UCB SA traded 26,955 shares on Tuesday, down about 20% from 33,632 the prior session, with the last trade at $148.33 versus the previous close of $144.61.
• Wolfe Research upgraded UCB to a Strong Buy on Feb. 23, and the stock's consensus rating is Buy (two Strong Buy ratings and one Hold).
• UCB, a Belgium‑founded global biopharmaceutical company, focuses on neurology and immunology and markets key branded drugs including CIMZIA, VIMPAT and NEUPRO.

UCB SA (OTCMKTS:UCBJY - Get Free Report) shares saw an uptick in trading volume on Tuesday . 26,955 shares traded hands during trading, a decline of 20% from the previous session's volume of 33,632 shares.The stock last traded at $148.33 and had previously closed at $144.61.

Wall Street Analyst Weigh In

Separately, Wolfe Research raised UCB to a "strong-buy" rating in a research report on Monday, February 23rd. Two research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy".

UCB Price Performance

The firm's 50-day moving average price is $152.57 and its 200 day moving average price is $143.06. The company has a current ratio of 1.35, a quick ratio of 1.01 and a debt-to-equity ratio of 0.29.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson's disease, rheumatoid arthritis and Crohn's disease.

The company's commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson's disease and restless legs syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.